title: Letter by Chin et al regarding article, "Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial analysis".
authors.affiliation: Department of Clinical Pharmacology, Christchurch Hospital, Christchurch, New Zealand.
authors.forename: Paul K L
authors.initials: PK
authors.lastname: Chin
authors.affiliation: School of Pharmacy, University of Otago, Dunedin, New Zealand.
authors.forename: Daniel F B
authors.initials: DF
authors.lastname: Wright
authors.affiliation: Canterbury Health Laboratories, Christchurch, New Zealand.
authors.forename: Christopher M
authors.initials: CM
authors.lastname: Florkowski
mesh_terms: D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000503:physiopathology*; D001562:Benzimidazoles / Q000009:adverse effects* / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007668:Kidney / Q000502:physiology*; D008297:Male; D014859:Warfarin / Q000009:adverse effects* / Q000627:therapeutic use*; D015091:beta-Alanine / Q000031:analogs & derivatives*
chemical_list: D001562:Benzimidazoles; D015091:beta-Alanine; D014859:Warfarin